The Subacute Necrotizing Encephalomyelopathy (Leigh Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Subacute Necrotizing Encephalomyelopathy (Leigh Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Subacute Necrotizing Encephalomyelopathy (Leigh Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Subacute Necrotizing Encephalomyelopathy (Leigh Disease) and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Subacute Necrotizing Encephalomyelopathy (Leigh Disease) by 14 companies/universities/institutes. The top development phase for Subacute Necrotizing Encephalomyelopathy (Leigh Disease) is preclinical with eight drugs in that stage. The Subacute Necrotizing Encephalomyelopathy (Leigh Disease) pipeline has 12 drugs in development by companies and three by universities/ institutes. Some of the companies in the Subacute Necrotizing Encephalomyelopathy (Leigh Disease) pipeline products market are: Ixchel Pharma, Stealth BioTherapeutics and Khondrion.
The key targets in the Subacute Necrotizing Encephalomyelopathy (Leigh Disease) pipeline products market include Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial (Cyclophilin D or Cyclophilin F or Mitochondrial Cyclophilin or Rotamase F or PPIF or EC 5.2.1.8), Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2), and NAD(P)H Dehydrogenase [Quinone] 1 (Azoreductase or DT Diaphorase or DTD or Menadione Reductase or NAD(P)H:Quinone Oxidoreductase 1 or Phylloquinone Reductase or Quinone Reductase 1 or NQO1 or EC 1.6.5.2).
The key mechanisms of action in the Subacute Necrotizing Encephalomyelopathy (Leigh Disease) pipeline product include cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35) Inhibitor with one drug in Unknown. The Subacute Necrotizing Encephalomyelopathy (Leigh Disease) pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Subacute Necrotizing Encephalomyelopathy (Leigh Disease) pipeline products market including Small Molecule, and Cell Therapy.
Subacute Necrotizing Encephalomyelopathy (Leigh Disease) overview
Subacute Necrotizing Encephalomyelopathy also known as Leigh Disease is a severe neurological disorder. It is a genetically heterogeneous disease characterized by progressive loss of mental and movement abilities and ultimately death. mutations in mitochondrial respiratory chain complexes causes depletion in the production of ATP causing SNE. It is a rare form commonly occurring in infants. vomiting, diarrhea, and difficulty swallowing, growth retardation, muscle movement problems are common signs and symptoms. No standard diagnostic criteria for SNE but commonly detected by a wide range of laboratory, molecular, and radiographic findings. CBP picture, CSF analysis, MI and chest X-ray are done. No standard therapy for SNE but symptomatic therapy is provided to treat acidosis with sodium bicarbonate, if seizures seen anti-epileptic medications, and nutraceutical support.
For a complete picture of Subacute Necrotizing Encephalomyelopathy (Leigh Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
